Evenity Shortage Update: What Patients Need to Know in 2026

If you've heard about drug shortages in the news and wondered whether Evenity (romosozumab) is affected, this article gives you the definitive answer for 2026 — along with an honest look at why some patients still face challenges accessing this medication even without an official shortage.

Is Evenity in an Official Shortage in 2026?

No. As of 2026, Evenity (romosozumab-aqqg) is NOT listed on either the FDA Drug Shortage Database or the ASHP (American Society of Health-System Pharmacists) drug shortage list. Amgen continues to manufacture and distribute Evenity without any reported supply disruptions. This is meaningfully different from medications like certain injectable generics or small-molecule drugs that have faced documented manufacturing shortages.

Why Do Patients Still Report Access Problems?

"No shortage" and "easy to get" are not the same thing for Evenity. Patients routinely experience delays and difficulties that feel like a shortage but have different causes:

Insurance prior authorization (PA): Nearly all insurance plans require prior authorization before covering Evenity. The PA process can take 2 to 4 weeks even when all paperwork is submitted correctly.

Step therapy: Many plans require documentation that you've already tried — and failed — a cheaper drug like alendronate (Fosamax) before they approve Evenity.

Specialty-only distribution: Evenity is not stocked at regular retail pharmacies. It flows through specialty pharmacy channels and must be shipped to your healthcare provider's office.

Cold chain and scheduling: Evenity requires refrigeration and administration by a healthcare provider, adding logistical complexity beyond a standard prescription.

High cost creating barriers: At ~$2,629 per monthly dose (over $31,500 for the full 12-month course), cost is a significant access barrier for uninsured or underinsured patients.

Has Evenity Ever Had a Supply Shortage?

There is no documented history of a national FDA-declared supply shortage for Evenity since its approval in April 2019. Unlike drugs that rely on complex generic ingredient supply chains, Evenity is a biologic manufactured by Amgen in controlled, purpose-built facilities with dedicated distribution channels. Amgen has not issued any shortage notices or supply alerts for Evenity.

What the Access Picture Looks Like in 2026

Medicare Part D spent approximately $567 million on Evenity in the most recent reporting period, covering about 32,000 beneficiaries. Spending has increased by 28.4% year-over-year, suggesting growing utilization. Despite this growth, Evenity's specialty biologic status means it remains a niche, often difficult-to-navigate medication for individual patients.

What Should You Do If You're Having Trouble Getting Evenity?

Here are the most effective steps for patients struggling with access:

Contact your prescriber's office to confirm prior authorization has been submitted with complete clinical documentation (DXA results, fracture history, prior treatments tried).

Enroll in Amgen SupportPlus (1-844-AMGEN-11). This program handles PA support, connects you with specialty pharmacies, and provides copay assistance.

If uninsured or underinsured, inquire about the Amgen Safety Net Foundation for free medication.

If PA is denied, ask your prescriber to file an appeal or request a peer-to-peer review with the insurer's medical director.

Use medfinder to locate pharmacies near you that can source Evenity. medfinder calls pharmacies on your behalf and texts you the results.

Bottom Line: Not a Shortage, But Still Challenging

Evenity is not in an official shortage in 2026. The challenges patients face are real but systemic — driven by insurance requirements and specialty distribution — not a manufacturing problem. The good news is there are well-established pathways and patient support resources to help. If Evenity remains out of reach, see our guide on alternatives to Evenity to discuss options with your prescriber.